DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a

DexCom, Inc. (DXCM) Revenue growth

Alert me on Revenue growth

DexCom, Inc.'s revenue growth over the twelve months to 30 June 2026 was 15.5%, down 0.1 percentage points from fiscal 2025 (15.6%). Over the past ten years it has ranged from 11.3% (fiscal 2024) to 55.1% (fiscal 2015); the current reading is higher than 18% of that period. That is above the Medical Devices industry median of 8.80% and above the Healthcare sector median of 8.27%.

Revenue growth, annual

Embed this chart

Annual newest first

Period Revenue growth Change (points)
FY2025 15.6% 4.26
FY2024 11.3% (13.15)
FY2023 24.5% 5.65
FY2022 18.8% (8.24)
FY2021 27.1% (3.46)
FY2020 30.5% (12.54)
FY2019 43.1% (0.50)
FY2018 43.6% 18.25
FY2017 25.3% (17.28)
FY2016 42.6% (12.48)

Quarterly newest first

Period Revenue growth Change (points)
Jun 2026 13.1% (1.97)
Mar 2026 15.1% 1.93
Dec 2025 13.1% (8.52)
Sep 2025 21.6% 6.43
42 more quarters

Against its own ten years

Low 11.3% High 55.1%
Ten-year median 27.1%
Current reading's percentile 18

Revenue growth against peers

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on DXCM